Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.9M	Buy	1,000,000 +500,000	+100%	+$31.8M	3.15%	5
2025 Q4	$31.8M	Sell	500,000 -250,000	-33%	-$15.6M	1.58%	17
2025 Q3	$41.2M	Buy	750,000 +250,000	+50%	+$10.3M	2.79%	6
2025 Q2	$16.5M	Buy	+500,000	New	+$17.4M	1.51%	25
2024 Q1	–	Sell	-400,000	Closed	-$33.4M	–	85
2023 Q4	$33.4M	Buy	+400,000	New	+$14.5M	4.55%	1
2023 Q1	–	Sell	-400,000	Closed	-$18.3M	–	75
2022 Q4	$18.3M	Sell	400,000 -56,300	-12%	-$2.42M	3.85%	1
2022 Q3	$22.1M	Buy	+456,300	New	+$22M	4.29%	2
2020 Q4	–	Sell	-200,000	Closed	-$4.33M	–	64
2020 Q3	$4.33M	Buy	+200,000	New	+$4.68M	1.32%	25

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q1 2026 in Review

Integral Health Asset Management increased its Cytokinetics (CYTK) stake by 14% in Q1 2026, buying an estimated $12.7M and bringing the position to 1,600,000 shares worth $105M. The position accounts for 5.04% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 25 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $105M as of Q1 2026.
Integral Health Asset Management bought 200,000 Cytokinetics shares in Q1 2026, an estimated $12.7M.
Cytokinetics made up 5.04% of Integral Health Asset Management's portfolio in Q1 2026, its #3 holding.
Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 25 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.